The endless battle for affordable cancer care
Published:
Source: The Hindu, 7 November 2026
Summary
- The NPPA has capped trade margins on 137 non-scheduled anti-cancer medicines, effective 9 November, with the Centre estimating annual savings of about ₹2,500 crore. Karnataka-based doctors and patient advocates welcome the move but say it is only a partial solution.
- The article links the order to Karnataka's complaint about 10x–52x markups on 253 medicines and consumables. It documents "financial toxicity" through patient examples and clinicians' accounts.
- An analysis by a Working Group on Access to Medicines and Treatments shows most price cuts but a large unchanged share, especially for single-source drugs. Clinicians call for pooled procurement, inclusion of immunotherapy in State insurance schemes, and transparent billing.
Key facts for Prelims
- NPPA: under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers; set up in 1997; implements DPCO 2013.
- DPCO 2013: scheduled formulations (NLEM) have ceiling prices; non-scheduled formulations face price monitoring and annual-increase limits.
- Para 19 of DPCO 2013: extraordinary powers in public interest, used for trade margin rationalisation.
- Trade-margin rationalisation: caps margins in the distribution and retail chain; the 2019 pilot covered 42 drugs. The 2026 order covers 137 non-scheduled anti-cancer drugs.
- PTR vs MRP: price to retailer vs maximum retail price.
- Pharma Sahi Daam app: used to check drug prices (NPPA).
- "Financial toxicity": the economic burden of treatment on patients, a term used in oncology.
- Ayushman Bharat–Arogya Karnataka (AB-ArK): the State's health insurance scheme (immunotherapy drugs are not covered, per the article).
- National Cancer Grid: runs a pooled-procurement pilot.
- Compulsory licensing is an option flagged for patented, single-source drugs.
Data and details
- NPPA order: 137 identified non-scheduled anti-cancer medicines; effective 9 November; trade margin capped at 30% (the article says "of the price to the retailer"); Centre's estimated annual saving about ₹2,500 crore; prices of some medicines to fall by up to 70%, varying across formulations and brands.
- Patient cases: a 45-year-old garment worker from Bengaluru Rural with stage IV-A mouth cancer (medicines and supportive drugs about ₹93,000, family income ₹28,000 per month); a 56-year-old Mysuru shopkeeper with recurrent, inoperable hypopharyngeal cancer. For him, bi-weekly immunotherapy would cost another ₹2.4 lakh to ₹8 lakh over the next 2–3 months, against income of ₹45,000 a month.
- Karnataka's complaint:
- On 23 September 2026, Karnataka Health Minister U.T. Khader wrote to Union Health Minister J.P. Nadda about pricing discrepancies in 253 medicines and consumables.
- Karnataka Food Safety and Drug Administration investigations found companies supply hospitals at heavily discounted landing prices while patients are billed at or near MRP, with markups from 10 times to over 52 times procurement cost.
- Examples (landing cost → MRP): Gufipol (Criticare) ₹86 → ₹4,528; Guficycline-50 ₹160 → ₹7,110; Terlitis ₹118 → ₹4,416; Taxocare 120 mg ₹1,000 → ₹21,617; Canmab 440 mg ₹6,600 → ₹57,457; Bevatas 400 mg ₹5,850 → ₹62,690.
- Cancer burden (Rajya Sabha, August 2026): Karnataka's annual incidence rose from 88,126 (2021) to 97,130 (2025), about 10.2%. Estimated cancer deaths rose from 48,290 to 53,253. In 2025 Karnataka accounted for about 6.2% of new cases and 6.1% of deaths. These are annual estimates, not prevalence.
- Kidwai Memorial Institute of Oncology: BPL patients get free treatment and drugs; about 22,176 new patients a year and over 3.7 lakh follow-up visits (director R. Krishnappa).
- Dr. U.S. Vishal Rao (Karnataka Health Dept's Vision Group for Cancer):
- Supportive medicines (growth factors, antiemetics, pain medication) can be up to 30% of treatment cost.
- For middle-class families earning ₹25,000–45,000 a month, a single overpriced vial can wipe out a quarter's grocery and education budget.
- A four-month mouth-cancer treatment (paclitaxel, cisplatin, growth factors, pain medication) can cross ₹1 lakh in pharmacy bills in private tertiary centres.
- Some patients discontinue after two or three cycles, delay cycles or stretch the interval. He says the cap improves compliance, survival rates and household stability, and that the next frontier is making bi-weekly immunotherapy and targeted agents such as Cetuximab affordable.
- Working Group on Access to Medicines and Treatments (643 product entries):
- 484 entries (75.27%) saw price cuts averaging 50.78%; 159 (24.73%) saw no change.
- Combined MRP value fell from about ₹2.51 crore to ₹2.17 crore, about ₹34.57 lakh or 13.8%. Unchanged products account for 86.2% of combined revised MRP value.
- The calculations are unweighted by sales, prescriptions or use, so they are not an estimate of patient savings.
- 56 medicines have a single manufacturer or supplier, with almost all their brand entries unchanged.
- Recommendations: closer scrutiny of manufacturer pricing, affordability assessments, compulsory licensing where appropriate, and regulation of overall charges for cancer treatment.
- Dr. Pavan T. Sugoor (Kidwai): the National Cancer Grid pooled-procurement pilot covered 40 high-value oncology and supportive-care medicines across 23 centres and showed substantial savings against MRP. He called for expansion, quality assurance, storage, traceability, continuity of supply, written cost estimates and financial counselling in the private sector.
- Tata Memorial Centre study of 500 breast cancer patients: average out-of-pocket expenditure about ₹1.86 lakh, or 72.2% of total treatment cost.
- Dr. Krishnappa has appealed to include immunotherapy under AB-ArK. Patients from across the region travel to Bengaluru, adding travel, accommodation and loss of income.
Static–dynamic linkage
- Drug pricing in India has two layers. Under DPCO 2013, scheduled (NLEM) formulations have ceiling prices, while non-scheduled drugs are only monitored with a limit on annual price rises. Trade-margin rationalisation (TMR) reaches non-scheduled drugs by capping the distribution chain's margin without fixing manufacturer prices.
- The article's core insight is that TMR cuts distribution-chain markups, but it does not touch manufacturer-set prices. It has little effect for single-source or patented drugs, which can remain unaffordable.
- High out-of-pocket expenditure (OOPE) causes "financial toxicity": patients discontinue treatment or delay cycles. This is a health-equity and universal health coverage (UHC) issue.
Syllabus mapping: GS2 – Social Justice: health sector issues, welfare schemes; GS3 – Economy: price regulation and market failure in pharmaceuticals; GS3 – S&T: access to new therapies; IPR (compulsory licensing)
Background primer
National Pharmaceutical Pricing Authority (NPPA)
- What it is:
- An authority under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It is the statutory authority responsible for implementing drug price controls under the Drugs (Prices Control) Order, 2013.
- Founded:
- Established in 1997 and functions under the Ministry of Chemicals and Fertilisers.
- Mandate:
- Implements and enforces the DPCO and monitors drug availability and shortages. For scheduled formulations, ceiling prices are fixed on a market-based method, generally the simple average of brand prices with at least 1% market share. Non-scheduled medicines are subject to price monitoring and limits on annual price increases.
- Why it matters:
- To ensure essential medicines are available at reasonable prices while balancing manufacturer viability.
Drugs (Prices Control) Order, 2013 — Paragraph 19 and Trade Margin Rationalisation
- What it is:
- In 2019, the NPPA invoked its extraordinary powers in public interest under Para 19 of DPCO 2013 to bring 42 non-scheduled anti-cancer drugs under price control via Trade Margin Rationalisation.
- Why it matters:
- To correct excessive distribution and retail markups without regulating manufacturers' own prices.
Additional context
- The NPPA's TMR of 137 non-scheduled anti-cancer drugs was notified by Gazette on 17 October 2026, with revised prices effective 9 November 2026. An Expert Committee of oncologists, medical specialists, hospital experts and government officers recommended the 137 drugs.
- The list includes immunotherapy drugs for over 20 cancer types, denosumab, pegfilgrastim and bevacizumab, with pembrolizumab, durvalumab and osimertinib among the widely used drugs.
- Manufacturers must inform NPPA of revised prices within 7 days of the Gazette notification. Hospitals are responsible for ensuring revised prices, and State Drug Controllers will ensure compliance. Consumers can check revised prices on the Pharma Sahi Daam app and the NPPA website.
- Manufacturers must maintain current production and supply levels of the notified formulations.
- On 3 November 2026 the NPPA updated its revised MRP list covering 1,085 anti-cancer medicine brand entries.
- On 27 October 2026 the Supreme Court reserved its order on petitions about medicine prices and trade margins, noting that 90% of medicines fall outside price control. The Court asked why TMR applied only to anti-cancer drugs and whether a uniform cap of about 16% over PTR could apply to all non-patented medicines.
Mains dimensions
- Scope and limits of TMR: Cuts the distribution chain's margin (benefit mostly where markups were large) but leaves manufacturer-set prices. With 75% of entries cut but 86.2% of MRP value unchanged, the effect is uneven, and it is weakest for single-source or patented drugs (56 medicines).
- Hospital-level markups: Karnataka's evidence (10x–52x landing-to-MRP gaps) shows markups concentrated in institutional supply. The article links this to regulating overall treatment charges and to transparent billing.
- Financial toxicity and equity: Treatment abandonment after 2–3 cycles undermines survival and wastes initial spending. Young patients face career and education disruption. The TMC study (72.2% OOPE) shows the scale.
- Public procurement and insurance: Pooled procurement (NCG pilot), tendering and negotiated pricing, and including immunotherapy and targeted therapy in State schemes like AB-ArK are the complementary levers.
- Implementation risks: Stock-outs, emergency purchases at higher rates, and whether savings reach patients. Monitoring should cover availability, treatment delays and actual out-of-pocket spend.
- Federal angle: A State (Karnataka) flagged the problem to the Centre; the Centre's price regulation (NPPA) interacts with State drug controllers and State insurance schemes.
- Way forward: Extend TMR and price scrutiny to manufacturer prices; consider compulsory licensing and price negotiation for patented drugs; boost early detection and public-sector oncology capacity; strengthen quality assurance and cost transparency.
Possible Mains question
**GS2, 15 marks:** "Capping trade margins on anti-cancer drugs is a welcome step, but affordability of cancer care requires much more. Discuss the limits of trade-margin regulation and suggest a comprehensive approach to reducing out-of-pocket expenditure on cancer treatment in India."
Related topics
- National List of Essential Medicines (NLEM) and DPCO 2013
- Ayushman Bharat PM-JAY; out-of-pocket expenditure and National Health Accounts
- Compulsory licensing (Patents Act, 1970) and TRIPS flexibilities
- Jan Aushadhi and pooled procurement models (e.g., TN Medical Services Corporation)
- National Programme for Prevention and Control of Cancer, Diabetes, CVD and Stroke (NPCDCS)
Topics: GS2Economy
All current affairs of 7 November 2026 → · UPSC Current Affairs